BioSpace News Archive

Essential Pharma announces that it has completed the acquisition of HALDOL® and HALDOL® Decanoate from Janssen Pharmaceutica NV.

Touchlight announces a development and supply agreement with Odimma Therapeutics, a French biotech company focusing on personalised cancer immunotherapy.

Metrion Biosciences Limited and The KCNC1 Foundation announced a collaboration to progress a hit identification research project for small molecule modulators of the potassium ion channel Kv3.1, targeting KCNC1-related disorders.

Edison Partners, a leading growth equity investment firm, today announced it is leading a $21 million investment round in Lokavant, the leading clinical trial intelligence company.

Paragon Therapeutics today announced the launch of Apogee Therapeutics, LLC, its first spinout.

Bio-Path Holdings, Inc., today announced the enrollment and dosing of the first patient in a Phase 1/1b clinical trial of BP1001-A (liposomal Grb2) in patients with solid tumors, including ovarian, endometrial, pancreatic and breast cancer.

Prometheus Biosciences, Inc. today reported results from its ARTEMIS-UC Phase 2 and APOLLO-CD Phase 2a studies of PRA023 demonstrating strong efficacy and favorable safety results in both studies.

UCB, a global biopharmaceutical company, today announced that The Lancet has published two articles detailing 24-week results from the Phase 3 BE OPTIMAL study and 16-week results from the Phase 3 BE COMPLETE study, evaluating the efficacy and safety of bimekizumab in the treatment of adults with active psoriatic arthritis.

Axsome Therapeutics, Inc. today announced that treatment with AUVELITY® (dextromethorphan HBr-bupropion HCl) resulted in rapid, substantial, and durable improvements in cognitive and physical functioning in the EVOLVE open-label trial in major depressive disorder (MDD).

Berkshire Biomedical Corporation today announced that it has been awarded the second phase of a two-phase Fast-Track Small Business Innovation Research (SBIR) grant (1R44DA057185-01) from the National Institutes of Health’s (NIH) National Institute of Drug Abuse (NIDA).